Back to Search Start Over

The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.

Authors :
Ascierto PA
Warner AB
Blank C
Caracò C
Demaria S
Gershenwald JE
Khushalani NI
Long GV
Luke JJ
Mehnert JM
Robert C
Rutkowski P
Tawbi HA
Osman I
Puzanov I
Source :
Journal of translational medicine [J Transl Med] 2022 May 10; Vol. 20 (1), pp. 200. Date of Electronic Publication: 2022 May 10.
Publication Year :
2022

Abstract

The Great Debate session at the 2021 Melanoma Bridge virtual congress (December 2-4) featured counterpoint views from experts on seven important issues in melanoma. The debates considered the use of adoptive cell therapy versus use of bispecific antibodies, mitogen-activated protein kinase (MAPK) inhibitors versus immunotherapy in the adjuvant setting, whether the use of corticosteroids for the management of side effects have an impact on outcomes, the choice of programmed death (PD)-1 combination therapy with cytotoxic T-lymphocyte-associated antigen (CTLA)-4 or lymphocyte-activation gene (LAG)-3, whether radiation is needed for brain metastases, when lymphadenectomy should be integrated into the treatment plan and then the last debate, telemedicine versus face-to-face. As with previous Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their respective personal view. Audiences voted both before and after each debate.<br /> (© 2022. The Author(s).)

Details

Language :
English
ISSN :
1479-5876
Volume :
20
Issue :
1
Database :
MEDLINE
Journal :
Journal of translational medicine
Publication Type :
Academic Journal
Accession number :
35538491
Full Text :
https://doi.org/10.1186/s12967-022-03406-7